Seegene Inc (096530) Stock Price & News

096530:KOSDAQ

Seegene Inc

₩31,400.00

-1.57%

(-500.00) 1D

Sep 7, 3:30:20 PM GMT+9 · KRW

All symbols

YTD

MAX

	Symbol	Price	Change	% Change

Generating top insights for 096530...

Open

₩31,950

High

₩31,950

Low

₩31,200

Mkt. cap

1.64T

Avg. vol.

361.09K

Volume

144.75K

Dividend

3.82%

Quarterly dividend

₩300

Ex-dividend date

Sep 29, 2026

P/E ratio

17.98

52-wk high

₩35,750

52-wk low

₩21,700

EPS

₩1,746

Shares outstanding

52.23M

No. of employees

761

Open

₩31,950

High

₩31,950

Low

₩31,200

Mkt. cap

1.64T

Avg. vol.

361.09K

Volume

144.75K

Dividend

3.82%

Quarterly dividend

₩300

Ex-dividend date

Sep 29, 2026

P/E ratio

17.98

52-wk high

₩35,750

52-wk low

₩21,700

EPS

₩1,746

Shares outstanding

52.23M

No. of employees

761

Related stocks

Profile

Seegene, Inc is a Korean manufacturer of in vitro diagnostic products, particularly molecular diagnostics. Its portfolio includes a range of assays and screening products for sepsis, respiratory diseases such as influenza and respiratory syncytial virus, as well as sexually transmitted infections. It was founded in 2000. In early 2020, it began developing and distributing a range of tests for SARS-CoV-2, the virus that causes COVID-19. Along with its headquarters in Seoul, South Korea, the company has subsidiaries in the U.S., Canada, Germany, Italy, Mexico, Brazil, and the Middle East. In September 2010, Seegene undertook a $16.6 million initial public offering to list on KOSDAQ, a trading board of Korea Exchange. Wikipedia

About Seegene Inc

CEOJong Yun Cheon

Employees761

FoundedSep 16, 2000

Headquarters-

SectorBiotechnology

Websiteseegene.co.kr

All values in KRW	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	113.54B	130.63B	129.14B	135.96B
Cost of goods sold	42.43B	45.81B	42.45B	41.22B
Cost of revenue	42.43B	45.81B	42.45B	41.22B
Research and development expenses	15.06B	17.64B	13.70B	12.41B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	38.79B	51.71B	40.98B	51.60B
Operating expense	61.51B	77.88B	63.14B	73.16B
Total operating expenses	103.93B	123.68B	105.59B	114.38B
Operating income	9.61B	6.95B	23.55B	21.58B
Other non operating income	-422.91M	2.31B	447.44M	383.74M
EBT including unusual items	18.50B	15.20B	39.32B	34.52B
EBT excluding unusual items	20.32B	20.82B	41.11B	31.44B
Income tax expense	3.89B	10.21B	4.57B	8.57B
Effective tax rate	21.05%	67.19%	11.63%	24.81%
Other operating expenses	-	-	-	-
Net income	14.56B	4.94B	34.73B	25.94B
Net profit margin	12.82%	3.78%	26.89%	19.08%
Earnings per share	-	-	-	-
Interest and investment income	2.47B	4.81B	2.50B	3.71B
Interest expense	-1.31B	-603.99M	-936.74M	-1.04B
Net interest expenses	1.16B	4.21B	1.57B	2.68B
Depreciation and amortization charges	7.14B	7.29B	7.93B	8.16B
EBITDA	26.99B	24.01B	40.12B	37.90B
Gain or loss from assets sale	85.78M	121.04M	9.05M	-530.55M

Finance

Ask anything